ClinicalTrials.gg
RecruitingNCT07439991Updated Feb 27, 2026

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

An observational study in Lung Cancer (Diagnosis), Deep Vein Thrombosis (DVT) and Venous Thromboembolism (VTE), sponsored by The First Hospital of Jilin University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by The First Hospital of Jilin University · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
78th of 259
900 · median 307
Started
2024
with 112 others
Observational
259 of 850
114 open now
Primary completion
2029-11
later than 390 of 422 live
Registered
762nd of 850
by date

Among the 850 studies in Lung Neoplasms with a site in China, this one is the 78th largest by planned enrollment of the 259 observational ones that give a count, is one of 113 that started in 2024, is one of 259 observational ones, reaches primary completion later than 390 of the 422 other live ones, and was the 762nd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 376 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 850 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is:

Which clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk?

Participants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.

03

Conditions studied

  • Lung Cancer (Diagnosis)
  • Deep Vein Thrombosis (DVT)
  • Venous Thromboembolism (VTE)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients undergoing surgical resection for lung cancer at the Department of Thoracic Surgery, First Hospital of Jilin University. Participants will be prospectively followed for 30 days postoperatively to assess the occurrence of deep vein thrombosis (DVT) and to identify perioperative risk factors. All patients meeting inclusion criteria and without exclusion criteria will be eligible.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Patients undergoing surgical resection for lung cancer
  3. Postoperative hospital stay ≥ 48 hours
  4. Availability of perioperative clinical, laboratory, and imaging data
  5. Willingness to provide and participate in 30-day follow-up

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery
  2. Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks
  3. Severe coagulation disorders or bleeding diseases
  4. Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection
  5. Concurrent major organ surgery (e.g., cardiac, liver surgery)
  6. Pregnancy or lactation
  7. Incomplete postoperative follow-up data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • VTE Group

    Adult patients undergoing lung cancer surgery who develop postoperative deep vein thrombosis (DVT) within 30 days. Perioperative clinical, laboratory, and imaging data will be collected to identify risk factors and build predictive models.

    Other: Prospective Perioperative Data Collection

  • Non-VTE Group

    Adult patients undergoing lung cancer surgery who do not develop postoperative DVT within 30 days. Perioperative clinical, laboratory, and imaging data will be collected for comparison with the VTE group.

    Other: Prospective Perioperative Data Collection

Interventions

  • OtherProspective Perioperative Data Collection

    The intervention involves the prospective collection of perioperative clinical, laboratory, and imaging data from adult patients undergoing lung cancer surgery. No therapeutic or diagnostic procedures beyond standard care are applied. Collected data will be used to identify risk factors for postoperative deep vein thrombosis (DVT) and to develop machine learning-based predictive models.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients

    The primary outcome is the occurrence of postoperative deep vein thrombosis (DVT) within 30 days after lung cancer surgery, confirmed by Doppler ultrasound of the lower extremities. Perioperative clinical, laboratory, and imaging variables will be collected prospectively and analyzed to identify risk factors and develop machine learning-based predictive models for individual DVT risk.

    Time frame: From the day of lung cancer surgery to 30 days postoperatively

Secondary outcomes

  1. Identification of perioperative risk factors for postoperative deep vein thrombosis (DVT) in lung cancer surgery patients

    Secondary outcomes include the evaluation of clinical, surgical, and laboratory variables associated with postoperative DVT within 30 days. Variables such as age, sex, BMI, comorbidities, tumor characteristics, operative details, and perioperative laboratory results will be analyzed using multivariate logistic regression and machine learning models to identify independent predictors of DVT.

    Time frame: From the day of surgery to 30 days postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2029, 60 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 60 months is close to that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Feb 27, 2026
StartActual
Nov 1, 2024
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 30, 2029
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07439991
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Nov 1, 2024
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Feb 27, 2026

Study contacts

Wei Liu
Contact
l_w01@jlu.edu.cn
86-13596083366

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion